<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963713</url>
  </required_header>
  <id_info>
    <org_study_id>BYSY-CKIMRT-SPNALM</org_study_id>
    <nct_id>NCT03963713</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy and Image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors</brief_title>
  <acronym>SCIRSM</acronym>
  <official_title>Stereotactic Radiotherapy and Conventionally-fractionated-image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors：A Prospective Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mianyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao chengyang hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hiser Medical Center of Qingdao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The fifth medical center of PLA general hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Ruikang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital of Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GEM flower hospital of Liaohe oil field</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or
      conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center
      of the research group from July 2019 to June 2021 will be collected, as well as their
      follow-up data.Previous treatment and follow-up data will be analyzed to evaluate the
      clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated
      image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control
      rate and side effects, and to clarify the effectiveness and safety of different doses of
      radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, Data of 100 patients with spinal metastatic tumor who received stereotactic
      radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in
      the multi-center of the research group from July 2019 to June 2021 will be collected, as well
      as their follow-up data.The metastases were treated with SBRT.Using multimodal image fusion
      to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED
      value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal
      tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance
      between the tumor and gastrointestinal tract or spinal cord was less than 5 mm
      (alpha/beta=10).The metastases were treated with Conventionally-fractionated image- guided
      Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The
      dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and
      follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic
      radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy
      for spinal metastatic tumors, local control rate and side effects, and to clarify the
      effectiveness and safety of different doses of radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>non-randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer pain score</measure>
    <time_frame>1 year after the treatment</time_frame>
    <description>Numerical grading (NRS) should be used for pain intensity assessment, and facial expression pain scoring should be used for patients with difficulty in expression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle strength and muscle tension grading</measure>
    <time_frame>1 year after the treatment</time_frame>
    <description>Muscle strength and muscle tension were graded by Numbers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>JOA score of cervical and lumbar vertebrae</measure>
    <time_frame>2 years after the treatment</time_frame>
    <description>JOA score of cervical and lumbar vertebrae</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Score of Tumor Patients(0-60)</measure>
    <time_frame>2 years after the treatment</time_frame>
    <description>Common methods for evaluating the quality of life of patients:The full score of quality of life is 60, the worst is &lt; 20, the worse is 21-30, the average is 31-40, the better is 41-50, and the good is 51-60.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of pain response</measure>
    <time_frame>1 years after the treatment</time_frame>
    <description>Time from complete or partial pain relief to pain worsening (≥ 3 points on the NRPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years after the treatment</time_frame>
    <description>The time from enrollment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>3 years after the treatment</time_frame>
    <description>The rate at which lesions remained stable during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>6 months after the treatment</time_frame>
    <description>Adverse reactions during and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years after the treatment</time_frame>
    <description>Time from treatment to cancer progression or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Radiotherapy</condition>
  <condition>Spine Metastases</condition>
  <condition>Radiosurgery</condition>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, the metastases were treated with Stereotactic radiotherapy（SBRT）.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
Stereotactic radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventionally-fractionated image- guided Intensity modulated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, the metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy</intervention_name>
    <description>Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).</description>
    <arm_group_label>Stereotactic radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventionally-fractionated image- guided Intensity modulated radiotherapy</intervention_name>
    <description>Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.</description>
    <arm_group_label>Conventionally-fractionated image- guided Intensity modulated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years old;

          -  Spine metastatic tumor patients confirmed by pathology and imaging; Number 3; Surgical
             treatment is not possible due to iatrogenic or (and) personal factors;

          -  Spinal metastasis after previous systemic treatment or progression after previous
             treatment of spinal metastasis;

          -  The anatomy of the spinal metastases form Tomita parting Ⅰ type - Ⅲ type; Without
             systemic metastasis or metastasis, the lesion was controlled.

          -  ECOG physical condition score: 0-1, Karnofsky score 60, able to withstand puncture;

          -  Expected survival 3 months;

          -  Main organ function is good, without serious hypertension, diabetes and heart disease.

          -  Has signed informed consent;

          -  The compliance was good and the family members agreed to follow up for survival.

        Exclusion Criteria:

          -  Of the anatomy of the spinal metastases form Tomita classification: Ⅳ, Ⅴ Ⅵ, Ⅶ.

          -  Participated in other drug clinical trials within four weeks; There was a history of
             bleeding, and any bleeding event with severe grade of CTCAE5.0 or above occurred
             within 4 weeks before screening;

          -  Screening of patients with known central nervous system metastasis or a history of
             central nervous system metastasis. For patients with clinical suspected central
             nervous system metastasis, CT or MRI examination must be performed within 14 days
             before randomization to exclude central nervous system metastasis.

          -  Patients with hypertension who cannot obtain good control by single antihypertensive
             drug treatment (systolic blood pressure &gt;140mmHg, diastolic blood pressure &gt;90mmHg);
             Having a history of unstable angina pectoris; Patients newly diagnosed with angina
             within 3 months before screening or myocardial infarction within 6 months before
             screening; Arrhythmia (including QTcF: 450ms in male and 470ms in female) requires
             long-term use of anti-arrhythmia drugs and New York heart association grade II cardiac
             dysfunction;

          -  Long-term unhealed wounds or incomplete fracture healing;

          -  Imaging showed that the tumor had invaded important blood vessels or the researchers
             judged that the patient's tumor had a very high possibility to invade important blood
             vessels during the treatment and cause fatal bleeding;

          -  Coagulation function is unusual, have haemorrhage tendency person (before random 14
             days must satisfy: below the circumstance that does not use anticoagulant INR is in
             normal value range); Patients treated with anticoagulants or vitamin K antagonists
             such as warfarin, heparin or their analogues; The use of low-dose warfarin (1mg oral,
             once daily) or low-dose aspirin (no more than 100mg daily) for preventive purposes is
             permitted on the premise that the international standardized ratio of prothrombin time
             (INR) is 1.5;

          -  Screening for the occurrence of hyperactive/venous thrombosis events in the first 6
             months, such as cerebrovascular accidents (including temporary ischemic attack), deep
             vein thrombosis (except for venous thrombosis caused by intravenous catheterization in
             the early stage of chemotherapy, which was determined by the researchers to have
             recovered) and pulmonary embolism, etc.

          -  Thyroid function was abnormal in the past and could not be kept within the normal
             range even in the case of drug treatment.

             (10) Attending has a history of psychotropic drug abuse, and can't attend or has
             mental disorder;

          -  Always half a year after spinal tumors or other close to the spine tumor lesion
             lesions radiation;

          -  Immunodeficiency disease, or has other acquired, congenital immunodeficiency disease,
             or has a history of organ transplantation;

          -  Judgment according to the researchers, there is serious to endanger the safety of
             patients or patients completed the research associated with disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junjie Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fei Xu, M Med</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hongqing Zhuang, M Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaobo Du, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mianyang Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Li, M Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mianyang Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiang Song, M Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Hospital of Shanxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Zhang, M Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Hospital of Shanxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianguo Zhang, M Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qingdao chengyang people's hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peng Liu, M Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiser Medical Center of Qingdao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xuezhang Duan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The fifth medical center of PLA general hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zuping Lian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Ruikang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liang Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital of Guizhou Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Longhai Shen, M Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>GEM flower hospital of Liaohe oil field</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dongjie He, M Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tang-Du Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xuemin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junjie Wang, MD</last_name>
    <phone>+860182264910</phone>
    <email>junjiewang_edu@sina.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fei Xu, M Med</last_name>
    <phone>+8618511866032</phone>
    <email>xufeibysy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junjie Wang, MD</last_name>
      <phone>+8682264910</phone>
      <email>junjiewang_edu@sina.cn</email>
    </contact>
    <contact_backup>
      <last_name>Fei Xu, M Med</last_name>
      <phone>+8618511866032</phone>
      <email>xufeibysy@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Junjie Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fei Xu, M Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongqing Zhuang, M Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xuemin Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The fifth medical center of PLA general hospital</name>
      <address>
        <city>BeiJing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XueZhang Duan, M Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi ruikang hospital</name>
      <address>
        <city>NanNing</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZuPing Lian, M Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>GuiYang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Liu, M D</last_name>
      <email>jinshatanwo@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GEM flower hospital of Liaohe oil field Tang-Du Hospital</name>
      <address>
        <city>Panjin</city>
        <state>Liaoning</state>
        <zip>124010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Longhai Shen, M Med</last_name>
    </contact>
    <investigator>
      <last_name>Long hai Shen, M Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiser Medical Center of Qingdao</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Liu, M Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao chengyang people's hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JanGuo Zhang, M Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of Shanxi Medical University</name>
      <address>
        <city>TaiYuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Song, M Med</last_name>
      <email>songxianggeryuan@163.cob</email>
    </contact>
    <investigator>
      <last_name>Lei Zhang, M Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tangdu hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DongJie He, M Med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mianyang Central Hospital</name>
      <address>
        <city>Mianyang</city>
        <state>Sichuan</state>
        <zip>621000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaobo Du, MD</last_name>
      <phone>+8613550822229</phone>
      <email>duxiaobo2005@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jie Li, M Med</last_name>
      <phone>+8615228324561</phone>
      <email>lijie.7181@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaobo Du, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Li, M Med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Massicotte E, Foote M, Reddy R, Sahgal A. Minimal access spine surgery (MASS) for decompression and stabilization performed as an out-patient procedure for metastatic spinal tumours followed by spine stereotactic body radiotherapy (SBRT): first report of technique and preliminary outcomes. Technol Cancer Res Treat. 2012 Feb;11(1):15-25.</citation>
    <PMID>22181327</PMID>
  </reference>
  <reference>
    <citation>Sahgal A, Whyne CM, Ma L, Larson DA, Fehlings MG. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol. 2013 Jul;14(8):e310-20. doi: 10.1016/S1470-2045(13)70101-3. Review.</citation>
    <PMID>23816297</PMID>
  </reference>
  <reference>
    <citation>Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ, Obralic N, Bajrovic A, Rudat V, Schwarz R, Hulshof MC, Poortmans P, Schild SE. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005 May 20;23(15):3366-75.</citation>
    <PMID>15908648</PMID>
  </reference>
  <reference>
    <citation>Gong Y, Wang J, Bai S, Jiang X, Xu F. Conventionally-fractionated image-guided intensity modulated radiotherapy (IG-IMRT): a safe and effective treatment for cancer spinal metastasis. Radiat Oncol. 2008 Apr 22;3:11. doi: 10.1186/1748-717X-3-11.</citation>
    <PMID>18426607</PMID>
  </reference>
  <reference>
    <citation>Guckenberger M, Goebel J, Wilbert J, Baier K, Richter A, Sweeney RA, Bratengeier K, Flentje M. Clinical outcome of dose-escalated image-guided radiotherapy for spinal metastases. Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):828-35. doi: 10.1016/j.ijrobp.2008.11.017. Epub 2009 Feb 26.</citation>
    <PMID>19250762</PMID>
  </reference>
  <reference>
    <citation>Zhang M, Chen YR, Chang SD, Veeravagu A. CyberKnife stereotactic radiosurgery for the treatment of symptomatic vertebral hemangiomas: a single-institution experience. Neurosurg Focus. 2017 Jan;42(1):E13. doi: 10.3171/2016.9.FOCUS16372.</citation>
    <PMID>28041316</PMID>
  </reference>
  <reference>
    <citation>Gandhidasan S, Ball D, Kron T, Bressel M, Shaw M, Chu J, Chander S, Wheeler G, Plumridge N, Chesson B, David S, Siva S. Single Fraction Stereotactic Ablative Body Radiotherapy for Oligometastasis: Outcomes from 132 Consecutive Patients. Clin Oncol (R Coll Radiol). 2018 Mar;30(3):178-184. doi: 10.1016/j.clon.2017.11.010. Epub 2017 Dec 8.</citation>
    <PMID>29224900</PMID>
  </reference>
  <reference>
    <citation>Ryu S, Rock J, Rosenblum M, Kim JH. Patterns of failure after single-dose radiosurgery for spinal metastasis. J Neurosurg. 2004 Nov;101 Suppl 3:402-5.</citation>
    <PMID>15537196</PMID>
  </reference>
  <reference>
    <citation>Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, Weinberg JS, Brown BW, Wang XS, Woo SY, Cleeland C, Maor MH, Rhines LD. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine. 2007 Aug;7(2):151-60.</citation>
    <PMID>17688054</PMID>
  </reference>
  <reference>
    <citation>Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976). 2007 Jan 15;32(2):193-9.</citation>
    <PMID>17224814</PMID>
  </reference>
  <reference>
    <citation>Wowra B, Zausinger S, Drexler C, Kufeld M, Muacevic A, Staehler M, Tonn JC. CyberKnife radiosurgery for malignant spinal tumors: characterization of well-suited patients. Spine (Phila Pa 1976). 2008 Dec 15;33(26):2929-34. doi: 10.1097/BRS.0b013e31818c680a.</citation>
    <PMID>19092627</PMID>
  </reference>
  <reference>
    <citation>Expert Panel on Radiation Oncology-Bone Metastases, Lo SS, Lutz ST, Chang EL, Galanopoulos N, Howell DD, Kim EY, Konski AA, Pandit-Taskar ND, Rose PS, Ryu S, Silverman LN, Sloan AE, Van Poznak C. ACR Appropriateness Criteria ® spinal bone metastases. J Palliat Med. 2013 Jan;16(1):9-19. doi: 10.1089/jpm.2012.0376. Epub 2012 Nov 20.</citation>
    <PMID>23167547</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>July 18, 2019</last_update_submitted>
  <last_update_submitted_qc>July 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic radiotherapy</keyword>
  <keyword>Intensity modulated radiotherapy</keyword>
  <keyword>spinal metastatic tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

